Shield Therapeutics plc (STX) Fair Value & Analysis
Healthcare · GB · Market cap 62.6M GBX
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from £0.0600 to £0.0604 (+0.7%) since Jun 24, 2026. Share price +3.4% over the past month.
Price vs Fair Value (12 months)
12‑month range £0.0283 – £0.1210 · fair‑value band £0.0482 – £0.0726 · the £0.0610 price screens above the £0.0604 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Shield Therapeutics plc (STX) currently trades at £0.0610, while our model-based Fair Value estimate is £0.0604 — implying the stock looks roughly 1.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Shield Therapeutics plc generated revenue of £49.7M at a net margin of -35.5%. Revenue grew 40.9% year over year. Net debt stands at £18.5M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shield Therapeutics plc reported revenue of £50.7M in FY2025 versus £1.5M in FY2021, a compound +140.4%/yr. Reported net income was −£18.0M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shield Therapeutics plc (STX) undervalued?
What is the fair value of STX?
What is the quality score of STX?
What is the revenue of Shield Therapeutics plc (STX)?
What is the net profit margin of STX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.